5 Key Takeaways

• 1

  Onapgo, a drug-device combination, received FDA approval for treating movement-related symptoms in Parkinson’s disease.

• 2

  The treatment reduced daily 'off episode' duration by a mean of 2.6 hours compared to 0.9 hours with placebo.

• 3

  Onapgo delivers apomorphine continuously via subcutaneous infusion, unlike current injections requiring every 2 hours.

• 4

  The approval was based on the phase III TOLEDO trial, which assessed efficacy in patients with motor fluctuations.

• 5

  Analysts suggest Onapgo may have better tolerability than AbbVie’s Vyalev, with fewer injection site reactions.